ADVERTISEMENT
Gland Pharma Q4 Results Review: Core Weakness, Cenexi Hurdles Weigh On FY25 — Motilal Oswal Maintains 'Buy'
Cenexi’s production challenges at its Paris site and continuing normalcy at Belgium site moderated its YoY growth to 8% for Q4 FY25, adds Motilal Oswal
21 May 2025, 11:31 AM IST 
Gland Pharma's Q4 FY25 revenues declined by 7.3% YoY to Rs 14.2 billion. (Photo: company website)
Gland Pharma has faced deterioration in earnings over past three years due to increased competition in its base products and operational losses at its Cenexi business. Having said this, largely steady price erosion in the base portfolio, new launches across key markets, and improving operating performance of Cenexi would drive a 20% earnings CAGR over FY25-27.
I’m already a Subscriber
To continue reading this storySubscribe to Unlock & Enjoy your
Subscriber-Only benefits
Subscriber-Only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Subscriber-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Subscriber-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
